Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.44 |
| ▸ | F13A1 | P00488 | 11/20 | 0.44 |
| ▸ | TGM1 | P22735 | 8/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5742042 | 0.85 | F13A1 (0.38) | TGM2F13A1TGM1POLBPKM | |
| SCHEMBL5741924 | 0.84 | MAPT (0.42) | TGM2F13A1TGM1POLBPKM | |
| SCHEMBL5740527 | 0.83 | ATM (0.39) | TGM2F13A1TGM1SMN1; SMN2 | |
| SCHEMBL5741976 | 0.81 | ATM (0.37) | TGM2F13A1TGM1POLBPKM | |
| SCHEMBL5855055 | 0.81 | CYP2C9 (0.34) | TGM2F13A1TGM1POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5742036 | 0.80 | ATM (0.36) | TGM2F13A1TGM1POLBPKM | |
| SCHEMBL5740518 | 0.80 | ATM (0.36) | TGM2F13A1TGM1POLBTGM3 | |
| SCHEMBL5743483 | 0.79 | ATM (0.36) | TGM2F13A1TGM1POLBPKM | |
| SCHEMBL5741290 | 0.78 | CYP1A2 (0.37) | TGM2F13A1TGM1SMN1; SMN2 | |
| SCHEMBL5740189 | 0.76 | SMN1; SMN2 (0.39) | TGM2F13A1TGM1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109200-B2 | Carbamate derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-19 | — | — | US | disclosed |
| EP-1340753-B1 | CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-20040038986-A1 | Carbamate derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1340753-A1 | CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038986-A1 | Carbamate derivatives, process for producing the same and use thereof | CFH, F11, F2 | TGM2 1508/4885F13A1 18/4885TGM1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.